Capricor Therapeutics (NASDAQ: CAPR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.320 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Capricor Therapeutics (NASDAQ: CAPR) through any online brokerage.
Other companies in Capricor Therapeutics’s space includes: Alzamend Neuro (NASDAQ:ALZN), Fortress Biotech (NASDAQ:FBIO), HOOKIPA Pharma (NASDAQ:HOOK), Galectin Therapeutics (NASDAQ:GALT) and Curis (NASDAQ:CRIS).
The latest price target for Capricor Therapeutics (NASDAQ: CAPR) was reported by HC Wainwright & Co. on Monday, January 31, 2022. The analyst firm set a price target for 18.00 expecting CAPR to rise to within 12 months (a possible 389.13% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Capricor Therapeutics (NASDAQ: CAPR) is $3.68 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Capricor Therapeutics.
Capricor Therapeutics’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Capricor Therapeutics.
Capricor Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.